ClinicalTrials.gg
CompletedNCT04788017Updated Feb 15, 2022

A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Ziresovir in Healthy Subjects

A Phase 1 interventional study of Ziresovir and Placebo in Healthy Subjects, sponsored by Shanghai Ark Biopharmaceutical Co., Ltd.. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-02-15.

Sponsored by Shanghai Ark Biopharmaceutical Co., Ltd. · Phase 1, Interventional, and Health services research

From the registry’s dates

  • Primary completion was Jun 2021, 5 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a randomized, double-blind, placebo-controlled, dose escalation study to evaluate the safety, tolerability, and pharmacokinetics (PK) of ziresovir following a single ascending oral dose administration in healthy adult subjects under fasted conditions.

Read the detailed description

Up to 3 dose cohorts are planned. The ziresovir dose level of each cohort is determined based on the collective clinical and nonclinical data of ziresovir.

The proposed dose levels of Cohorts 1, 2 and 3 are 300 mg and up to 600 mg and up to 900 mg, respectively.

A total of up to 24 subjects will be randomized with 18 subjects to receive active drug and 6 subjects to receive placebo in a double-blind fashion. Eight subjects will be randomized in each dose cohort, with 6 subjects to receive active drug and 2 subjects o receive placebo.

02

Conditions studied

  • Healthy Subjects
03

In context

Lead sponsor

Shanghai Ark Biopharmaceutical Co., Ltd. is the lead sponsor of 20 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Capable of giving written and complying with study procedures;
  2. Between the ages of 18 and 55 years, inclusive;
  3. (BMI) of 18.0 to 32.0 kg/m2 inclusive and body weight not less than 50 kg;
  4. Female subjects must have a negative pregnancy test result at screening;
  5. Considered healthy by the Investigator, based on subject's reported medical history, full physical examination, 12-lead , and vital signs;
  6. Willing and being able to adhere to study restrictions and to be confined at the Clinical Research Unit.

Exclusion criteria

Exclusion Criteria:

  1. reported history of gastrointestinal, cardiovascular, musculoskeletal, endocrine, hematologic, psychiatric, renal, hepatic, bronchopulmonary, neurologic, immunologic, lipid metabolism disorders, or drug as determined by the Investigator;
  2. Poor venous access;
  3. Taken an drug or participated in a clinical trial evaluating an investigational drug or device within 30 days (or 5 half-lives) prior to the study drug dose, whichever is longer;
  4. Taken any prescription medications within 14 days or 5 half-lives (whichever is longer) of the study drug dose;
  5. Major surgery or hospitalization within 6 months prior to screening that in the Investigator's opinion would put the subject or study conduct at risk, or have any scheduled surgery or hospitalization during the study period;
  6. Any condition or finding that in the Investigator's opinion would put the subject or study conduct at risk if the subject were to participate in the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
24 participants (actual)

Study arms

  • Active comparator
    ziresovir

    The study drugs will be administered to subjects by CRU staff at approximately 8:00 a.m. (± 1 hour), following an overnight fast. Immediately following administration of the assigned dose of the study drugs, subjects will be given water such that their water consumption is approximately 240 mL as follows: * If administered 60 mL as the study drug dose, follow with approximately 180 mL water. * If administered 120 mL as the study drug dose, follow with approximately 120 mL water. * If administered 180 mL as the study drug dose, follow with approximately 60 mL water.

    Drug: Ziresovir

  • Placebo comparator
    placebo

    The study drugs will be administered to subjects by CRU staff at approximately 8:00 a.m. (± 1 hour), following an overnight fast. Immediately following administration of the assigned dose of the study drugs, subjects will be given water such that their water consumption is approximately 240 mL as follows: * If administered 60 mL as the study drug dose, follow with approximately 180 mL water. * If administered 120 mL as the study drug dose, follow with approximately 120 mL water. * If administered 180 mL as the study drug dose, follow with approximately 60 mL water.

    Other: Placebo

Interventions

  • Planned treatments are: * Cohort 1: 300 mg of ziresovir * Cohort 2: up to 600 mg of ziresovir * Cohort 3: up to 900 mg of ziresovir

    Also known as: AK0529

  • OtherPlacebo

    Planned treatments are: * Cohort 1: 300 mg of placebo * Cohort 2: up to 600 mg of placebo * Cohort 3: up to 900 mg of placebo

06

What researchers measure

Primary outcomes

  1. numbers of all AEs

    The Common Terminology Criteria for Adverse Events (CTCAE) Version 5 will be used to grade AEs

    Time frame: through study completion, an average of 22 days

  2. percentages of all AEs

    The Common Terminology Criteria for Adverse Events (CTCAE) Version 5 will be used to grade AEs

    Time frame: through study completion, an average of 22 days

  3. change from baseline in systolic and diastolic blood pressure

    blood pressure in millimeter of mercury

    Time frame: screen/day -1/day 1/day 2/day 3/day4

  4. change from baseline in pulse rate

    pulse rate in times per minute

    Time frame: screen/day -1/day 1/day 2/day 3/day4

  5. change from baseline in respiratory rate

    respiratory rate in times per minute

    Time frame: screen/day -1/day 1/day 2/day 3/day4

  6. change from baseline in oral temperature

    oral temperature in degree

    Time frame: screen/day -1/day 1/day 2/day 3/day4

  7. change from baseline in Prothrombin time/International Normalized Ratio

    INR is calculated from the PT and allows for worldwide standardization of results.

    Time frame: screen/day -1/day 2/day4

  8. change from baseline in Thrombin time

    Thrombin time in seconds

    Time frame: screen/day -1/day 2/day4

  9. change from baseline in activated Partial Thromboplastin time

    activated Partial Thromboplastin time in seconds

    Time frame: screen/day -1/day 2/day4

  10. change from baseline in Hemoglobin (Hgb) count

    Hemoglobin (Hgb) in gram per liter

    Time frame: screen/day -1/day 2/day4

  11. change from baseline in Hematocrit (Hct)

    Time frame: screen/day -1/day 2/day4

  12. change from baseline in Platelet count

    Platelet count per liter

    Time frame: screen/day -1/day 2/day4

  13. change from baseline in Red blood cell (RBC) count

    Time frame: screen/day -1/day 2/day4

  14. change from baseline in White blood cell (WBC) count with differential

    Time frame: screen/day -1/day 2/day4

  15. change from baseline in Specific gravity from urinalysis

    Time frame: screen/day -1/day 2/day4

  16. change from baseline in pH from urinalysis

    Time frame: screen/day -1/day 2/day4

  17. change from baseline in Protein from urinalysis

    Time frame: screen/day -1/day 2/day4

  18. change from baseline in Glucose from urinalysis

    Time frame: screen/day -1/day 2/day4

  19. change from baseline in Ketones from urinalysis

    Time frame: screen/day -1/day 2/day4

  20. change from baseline in Bilirubin from urinalysis

    Time frame: screen/day -1/day 2/day4

  21. change from baseline in Blood from urinalysis

    Time frame: screen/day -1/day 2/day4

  22. change from baseline in Nitrites from urinalysis

    Time frame: screen/day -1/day 2/day4

  23. change from baseline in Leukocytes from urinalysis

    Time frame: screen/day -1/day 2/day4

  24. change from baseline in Urobilinogen from urinalysis

    Time frame: screen/day -1/day 2/day4

  25. Incidence of abnormal Microscopic urine analysis

    Time frame: screen/day -1/day 2/day4

  26. change from baseline in heart rate-corrected QT interval from resting 12-lead ECGs

    ECGs will be performed after the subject has been supine for at least 5 minutes

    Time frame: screen/day -1/day1/day2/day4

  27. change from baseline in heart rate from resting 12-lead ECGs

    ECGs will be performed after the subject has been supine for at least 5 minutes

    Time frame: screen/day -1/day1/day2/day4

  28. change from baseline in QRS intervals from resting 12-lead ECGs

    ECGs will be performed after the subject has been supine for at least 5 minutes

    Time frame: screen/day -1/day1/day2/day4

  29. change from baseline in treatment-emergent T-wave morphology from resting 12-lead ECGs

    ECGs will be performed after the subject has been supine for at least 5 minutes

    Time frame: screen/day -1/day1/day2/day4

  30. change from baseline in appearance of U-waves from resting 12-lead ECGs

    ECGs will be performed after the subject has been supine for at least 5 minutes

    Time frame: screen/day -1/day1/day2/day4

  31. Incidence of abnormal physical findings

    full physical examination will be conducted at screening and an abbreviated physical exam will be conducted on Day -1 and Day 2. A symptom-directed physical exam will be conducted on Day 3 and Day 4.

    Time frame: screen/day -1/day2/day3/day4

Secondary outcomes

  1. To characterize the drug concentration of ziresovir following single ascending doses by oral administration in healthy adult male and female subjects

    Time frame: 0 (within 90 minutes prior to dosing) and 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8, 10, 12, 24, 48, and 72 hours post-dose

07

Study locations

1 site
  • Frontage
    Secaucus, New Jersey 07094, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2021 to primary completion in Jun 2021, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2021
First posted
Mar 9, 2021
StartActual
Mar 24, 2021
Primary completionActual
Jun 14, 2021
CompletionActual
Jul 22, 2021
Last update
Feb 15, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 15, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04788017
Lead sponsor
Shanghai Ark Biopharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Mar 9, 2021
Start date
Mar 24, 2021
Primary completion
Jun 14, 2021
Completion
Jul 22, 2021
Last update
Feb 15, 2022

Study contacts

Jimmy Gu
study director · Ark Biosciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ziresovir

Start the discussion